Combined analysis of LEDGF/p75 expression with CEA levels and KRAS and MSH2 mutation status can significantly improve prognostic accuracy in colorectal cancer patients by providing a more complete understanding of tumor behavior and progression. Here, MSH2 is linked to neoplasm.